Skip to main content
Hit enter to search or ESC to close
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
© 2023 VHIR Annual Report 2021.
Six Top Stories
Facts & Figures
Partners and Acknowledgements
VHIR Annual Report 2021